Pharmaceutical News

RSS

Study: Early improvements not sustained in patients treated with PRP injection for facet joint arthropathy

Early gains in pain relief, behavioral markers and function were not sustained in patients treated with platelet-rich plasma (PRP) injection for facet joint arthropathy, new research shows. Results were available at the 31st Annual Meeting of the American Academy of Pain Medicine.

25 Mar 2015

CMV-based vaccine provides long-lasting protective immunity against Ebola virus

A cytomegalovirus (CMV)-based vaccine provides long-lasting protective immunity against Ebola virus, and has potential for development as a disseminating vaccine strategy to prevent ebolavirus infection of wild African ape populations.

25 Mar 2015

Experimental drug that attacks brain tumor cells passes early tests

An experimental drug that attacks brain tumor tissue by crippling the cells' energy source called the mitochondria has passed early tests in animal models and human tissue cultures, say Houston Methodist scientists.

25 Mar 2015

TPU's submission of Docetaxel Injection Concentrate, Non-Alcohol Formula NDA acknowledged by FDA

Teikoku Pharma USA announced today that it has submitted a 505(b)(2) New Drug Application (NDA) to the U.S. Food and Drug Administration for Docetaxel Injection Concentrate, Non-Alcohol Formula on February 26, 2015 and received an acknowledgment of the receipt from FDA.

25 Mar 2015

Confluence pharmaceuticals signs co-development and marketing agreement with AOP orphan for fragile X syndrome drug

Confluence is a biopharmaceutical company focused on developing therapeutic treatments for Fragile X Syndrome and Autism Spectrum Disorders. AOP is an Austrian based company specializing in the development and marketing of medicines for rare and complex diseases.

24 Mar 2015

Study explains why COPD patients develop tolerance to roflumilast drug

Roflumilast, a drug recently approved in the United States to treat severe chronic obstructive pulmonary disease (COPD), increases the production of a protein that causes inflammation, which possibly results in patients developing a tolerance to the drug after repeated use and makes the drug less effective, according to researchers at Georgia State University, Kumamoto University and the University of Rochester Medical Center.

24 Mar 2015

Discontinuation of statin therapy may benefit patients with terminal illness

Discontinuing statin use in patients with late-stage cancer and other terminal illnesses may help improve patients' quality of life without causing other adverse health effects, according to a new study by led by researchers at the University of Colorado Anschutz Medical Campus and Duke University and funded by the National Institute of Nursing Research (NINR).

24 Mar 2015

Vitamin D3 and metformin show promising results in preventing colorectal cancer

The concept was simple: If two compounds each individually show promise in preventing colon cancer, surely it's worth trying the two together to see if even greater impact is possible.

24 Mar 2015

Glyxambi for Type 2 diabetes treatment now available by prescription across the U.S.

Glyxambi® (empagliflozin/linagliptin) tablets are now available by prescription in many leading chain and independent pharmacies across the U.S., including Walgreens and Rite Aid.

23 Mar 2015

Cipher to distribute Can-Fite’s CF101 for plaque psoriasis and rheumatoid arthritis treatment in Canada

Cipher Pharmaceuticals Inc. today announced it has licensed the Canadian distribution rights to CF101, a novel chemical entity being developed by Can-Fite Biopharma for moderate to severe plaque psoriasis and rheumatoid arthritis.

23 Mar 2015

Can-Fite, Cipher Pharmaceuticals sign agreement to distribute CF101 in Canada

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that are being developed to treat inflammatory diseases, cancer and sexual dysfunction, announced today it has signed a distribution agreement with Cipher Pharmaceuticals Inc. to distribute Can-Fite's lead drug candidate, CF101, for the treatment of moderate to severe psoriasis and rheumatoid arthritis in the Canadian market upon receipt of regulatory approvals.

23 Mar 2015

GenVec collaborates with TheraBiologics to develop NSC-mediated cancer therapeutics

GenVec, Inc. today announced that it has formed a collaboration with TheraBiologics to develop cancer therapeutics leveraging both GenVec's proprietary gene delivery platform and TheraBiologics' proprietary neural stem cell (NSC) technology.

23 Mar 2015

Study explores the efficacy of antivenom against copperhead snake bites

Dr. Spencer Greene wants to make sure the standard treatment for copperhead snake bites, the most common venomous snake in greater Houston and southeast Texas, works, and if it doesn't, he wants to stop its use.

23 Mar 2015

Study explains why generic insulin remains out of reach for diabetes patients

A generic version of insulin, the lifesaving diabetes drug used by 6 million people in the United States, has never been available in this country because drug companies have made incremental improvements that kept insulin under patent from 1923 to 2014.

23 Mar 2015

Stempeutics' Stempeucel drug receives ATMP classification from EMA for treatment of TAO

Stempeutics Research, a group company of Manipal Education and Medical Group and a Joint Venture with Cipla Group, announced today that the European Medicines Agency has granted Advanced Therapy Medicinal Product classification for its novel stem cell drug 'Stempeucel' which will be used for the treatment of Thromboangiitis Obliterans (TAO).

23 Mar 2015

Discovery may lead to new potential treatment for drug-resistant melanoma

In the last several years, targeted therapies - drugs that directly impact specific genes and proteins involved in the progression of cancer - have been approved for a wide variety of cancers, including melanoma, the deadliest form of skin cancer. Now, researchers at The Wistar Institute have discovered one way in which melanoma becomes resistant to a particular form of targeted therapy, and understanding this phenomenon may lead to a new melanoma target or prompt new designs of these treatments.

23 Mar 2015

Thomson Reuters releases 2015 edition of annual Drugs to Watch report

The Intellectual Property and Science business of Thomson Reuters, the world's leader in intelligent information for businesses and professionals, today released the 2015 edition of its annual Drugs to Watch report.

23 Mar 2015

Study finds no added benefit from sipuleucel-T in men with metastatic prostate cancer

Sipuleucel-T (trade name Provenge) has been approved since September 2014 for men with metastatic prostate cancer who have few or no symptoms and do not yet require chemotherapy. In the dossier assessment conducted by the German Institute for Quality and Efficiency in Health Care (IQWiG) in January 2015, no added benefit could be derived for sipuleucel-T.

22 Mar 2015

Amgen seeks marketing approval of Repatha (evolocumab) in Japan for treatment of high cholesterol

Amgen today announced that an application seeking marketing approval of Repatha (evolocumab) for the treatment of high cholesterol has been submitted for review to the Ministry of Health, Labour and Welfare in Japan.

21 Mar 2015

Eli Lilly, Innovent Biologics announce biotech drug development collaborations in China

Eli Lilly and Company and Innovent Biologics, Inc. today announced one of the largest biotech drug development collaborations in China to date between a multi-national and domestic company.

21 Mar 2015

Pharmaceutical News

Study: Early improvements not sustained in patients treated with PRP injection for facet joint arthropathy

CMV-based vaccine provides long-lasting protective immunity against Ebola virus

Experimental drug that attacks brain tumor cells passes early tests

TPU's submission of Docetaxel Injection Concentrate, Non-Alcohol Formula NDA acknowledged by FDA

Confluence pharmaceuticals signs co-development and marketing agreement with AOP orphan for fragile X syndrome drug

Study explains why COPD patients develop tolerance to roflumilast drug

Discontinuation of statin therapy may benefit patients with terminal illness

Vitamin D3 and metformin show promising results in preventing colorectal cancer

Glyxambi for Type 2 diabetes treatment now available by prescription across the U.S.

Cipher to distribute Can-Fite’s CF101 for plaque psoriasis and rheumatoid arthritis treatment in Canada

Can-Fite, Cipher Pharmaceuticals sign agreement to distribute CF101 in Canada

GenVec collaborates with TheraBiologics to develop NSC-mediated cancer therapeutics

Study explores the efficacy of antivenom against copperhead snake bites

Study explains why generic insulin remains out of reach for diabetes patients

Stempeutics' Stempeucel drug receives ATMP classification from EMA for treatment of TAO

Discovery may lead to new potential treatment for drug-resistant melanoma

Thomson Reuters releases 2015 edition of annual Drugs to Watch report

Study finds no added benefit from sipuleucel-T in men with metastatic prostate cancer

Amgen seeks marketing approval of Repatha (evolocumab) in Japan for treatment of high cholesterol

Eli Lilly, Innovent Biologics announce biotech drug development collaborations in China

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Latest News